Metraipolis › archive › dc_cb1665fd7684

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid… — Europe PMC PMID:42118353

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42118353
DOI
10.1007/s00280-[numero omesso]-z
License (as archived)
solo-consultazione
Archived
2026-10-08T16:29:37.062Z
SHA-256 of the archived text
61e496f4d2ca79837f09af6028e09dfe6498cb42b32d68d3e49cc31fe6edca20
Stable URL of this page
https://metraipolis.com/documento/dc_cb1665fd7684

How to cite

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid… — Europe PMC PMID:42118353 — Europe PMC (en), https://europepmc.org/article/MED/42118353 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cb1665fd7684 (Metraipolis archive dc_cb1665fd7684, sha256 61e496f4d2ca79837f09af6028e09dfe6498cb42b32d68d3e49cc31fe6edca20)
BibTeX
@misc{dccb1665fd7684,
  title = {Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid… — Europe PMC PMID:42118353},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42118353},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cb1665fd7684; sha256 61e496f4d2ca79837f09af6028e09dfe6498cb42b32d68d3e49cc31fe6edca20},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42118353. Agents can read the archived copy with the MCP tool read_document.